Overview
- Company: Recce Pharmaceuticals Ltd
- Indication: Diabetic Foot Infections
- Drug: RECCE® 327
- Trial Phase: Phase 1/2
- NCT ID: N/A
Trial Expansion Announcement
Recce Pharmaceuticals Ltd has expanded the patient recruitment for their ongoing Phase I/II clinical trial evaluating the synthetic anti-infective agent, RECCE® 327, for the treatment of Diabetic Foot Ulcer Infections.
Background
Diabetic foot infections (DFI) represent a significant medical challenge due to the rise of antibiotic-resistant bacterial pathogens. These complications often lead to lower limb amputations in severe cases.
Current Trial Progress
The decision to increase recruitment followed interim data analysis, which confirmed the primary endpoints of safety and efficacy were met. Topical application of RECCE® 327 has been shown to be both safe and effective, with the possibility of changing the paradigm of DFI treatment and potentially reducing the need for amputations.
Approval and Safety
The safety profile of RECCE® 327 has been endorsed by the Independent Safety Committee from Liverpool Hospital NSW. The trial involves administering the therapy either daily or bi-daily over two weeks.
Future Steps
Recce Pharmaceuticals plans to open additional clinical sites and extend the trial's reach globally. The ultimate goal is to create an accessible, non-invasive treatment option for DFU infections.
Statement from Recce Pharmaceuticals
Professor Hugh Dickson observed a rapid and efficacious response of DFU infections to RECCE® 327. CEO James Graham expresses his company's commitment to combating antimicrobial resistance. Recce continues to be recognized for its advanced synthetic polymer anti-infectives, adherence to automated manufacturing, and its status within the new antibiotics development pipeline acknowledged by the FDA and The Pew Charitable Trusts.
Conclusion
Recce Pharmaceuticals upholds its mission to deliver pharmaceutical excellence with its innovative treatments, aiming to address one of the most pressing health threats of our era – antimicrobial resistance.